Eli Lilly and Company’s development plans for mirikizumab took another step forward on 16 March as the pharma unveiled top-line data from the Phase III LUCENT-1 trial showing that the interleukin 23 (IL-23) blocker provided clinical remission of ulcerative colitis at 12 weeks and also hit all of the study’s secondary endpoints.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?